Paul Mampilly of Banyan Hill is out again with a stunning piece of teaser pitch that features on his newsletters profits unlimited. The teaser pitch is super low with an entry level of 97dollars per year for stock picking letters. According to Paul Mampilly, he has identified one of the leading companies globally offering Precision Medicine Revolution bringing a huge win to investors since it captures on health care market. Paul approaches the theme attention branding it the most significant medical breakthrough ever seen in history more than the combination of drugs, medical devices, and vaccinations. Read this article at Daily Forex Report.
According to medical experts, it’s the revolutionary approach needed to tackling of different diseases, and it will ignite and change the health revolution. Paul Mampilly says that the mid-western company has precipice breakthrough of the greatest medical globally that will help to treat the untreatable humanity diseases. The company has an investment portfolio of 1.5 billion dollars, and its central core is precision medicine by looking at an individual DNA and creating personalized medicine fitting the personal genetic makeup hence preventing diseases. The precision medicines doctors identify the best treatment and drugs that work best in preventing individualized patients from ever getting certain types of medicine and the best therapy for overcoming any existing diseases based on individual genes.
Paul Mampilly says the company dealing with precision medicine started in the 1990s with its Chief Executive Officer being a biotech pioneer aged 25 years old. The biotech pioneer is using his vast industry contacts to bring in the board the top scientific minds globally to work on the best hilltop facilities confirming the best of Thinkolators work. The company is boasts of leading in the medical care industry of molecular diagnostic using the DNA sequencing accessing the possibility of a person developing certain diseases and determining the drug therapy ideal for curing the illness.
The Myriad Genetics central headquarters are in Utah, and its primary target is different types of cancers ranging from breast to ovarian to prostate to uterine and rheumatoid arthritis. Myriad Genetics company stock performed quite well since the original Paul Mampilly teaser when the price ranged from $24 to 25. The Paul Mampilly report boasted the pricing, making it increase from 1.5 billion dollars stock to 2.2 billion dollars stocks. The company has become the global leading in breast cancer business launching the riskScore algorithm that helps to improve the assessments of family cancer risks based on combining of the family history data with the Myriads Genetic test of my Risk hereditary cancer. Read more about Paul on Interview.net.